No­var­tis ax­es a once 'first-in-class' prospect as an­oth­er JAK pro­gram fails to clear a risk/ben­e­fit analy­sis

The JAK class can count one more clin­i­cal fail­ure, the lat­est in a long string of set­backs that con­tin­ues to cloud the fu­ture of these ther­a­pies.

In its Q4 up­date to­day phar­ma gi­ant No­var­tis not­ed that it has swept out a pan-JAK pro­gram for CEE321. De­tails are scant, and the work was very much ear­ly-stage, but No­var­tis had held it up as a bright prospect be­fore for atopic der­mati­tis.

In their pipeline sum­ma­ry, the com­pa­ny not­ed that the pro­gram had been dis­con­tin­ued be­cause it had failed to clear the bar on risk/ben­e­fit.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER